Emergent Biosolutions opened lower at $6.01, compared with its previous close of $6.04. In the last trading session, the stock traded between $5.79 and $6.11. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Emergent Biosolutions is now worth
$ 16.62
Resulting in a loss of
$ 83.38 (83.38%)
Note: Past profits do not guarantee future returns.
Rating from 2 Analysts
Today's Change
$-0.15 (-2.50%)
Day High
$6.11
Day Low
$5.79
Day Open
$6.01
Prev Close
$6.04
Volume
8,26,948
1W Return
-0.27%
1M Return
-15.73%
3M Return
33.02%
6M Return
-34.20%
1Y Return
-45.87%
Market Cap ($ Mn)
303
PE Ratio
-
PB Ratio
0.89
PEG Ratio
-
ROE
9.83%
ROCE
11.20%
EPS (TTM)
$-0.64
1 Week
-0.27%
1 Month
-15.73%
3 Months
33.02%
6 Months
-34.20%
9 Months
-46.61%
Emergent BioSolutions Q3FY26 Results: FY26 revenue guidance cut to $645 million
FY26 revenue guidance cut to $600 million-$645 million from $645 million-$675 million. Revised outlook misses consensus estimate of $657.133 million. Q3FY26 revenue fell to $110 million from $231 million YoY. Year-to-date operating cash flow reached $122 million. Adjusted gross margin guidance raised to 45%-47%.
10 days agoEmergent BioSolutions CFO Richard Lindahl to retire in Dec 2026
Richard S. Lindahl to retire as CFO effective December 31, 2026. Frank Vargo appointed interim CFO starting January 1, 2027. Lindahl will serve as senior executive advisor until March 31, 2027. Transition supports Emergent's multi-year transformation strategy.
27 days agoPomerantz investigates Emergent BioSolutions over securities fraud claims
Pomerantz LLP investigates Emergent BioSolutions for potential securities fraud. Company reported $191.3 million non-cash impairment on NARCAN asset group. GAAP net loss of $180.2 million recorded for quarter ended June 30, 2026. Full year revenue guidance cut by approximately 10.8% at the midpoint. Stock price fell 29.58% to close at $5.31 per share on August 6, 2026.
1mo agoEmergent BioSolutions secures $24 million CYFENDUS contract modification
Emergent BioSolutions secures ~$24 million BARDA contract modification. Deal supports supply of CYFENDUS anthrax vaccine for US preparedness. Award complements earlier $21.5 million BioThrax delivery order. CYFENDUS approved in 2023 for post-exposure prophylaxis.
2mo agoEmergent BioSolutions secures Canada standing offer for NARCAN Nasal Spray
Emergent BioSolutions awarded standing offer by Government of Canada for NARCAN Nasal Spray. Contract effective October 1, 2026, through September 30, 2029, with two-year extension option. Procurement via competitive process allows call-ups by federal and provincial public sector bodies. New deal replaces existing agreement expiring September 2026 to ensure nationwide overdose response access.
2mo agoEmergent BioSolutions expands opioid awareness efforts in US and Canada
Emergent BioSolutions expands opioid awareness campaigns in the US and Canada. US effort partners with Release Recovery to visit college campuses this fall. Canadian initiative collaborates with baseball player Davis Schneider. WHO links opioids to nearly 80 percent of global drug-related deaths. Canada sees average of 15 daily opioid poisoning deaths since 2016.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $1,437.29 | +0.35% | $13,52,123.38M | 39.43 | |
| $280.41 | -0.13% | $6,75,033.80M | 31.06 | |
| $294.98 | +0.37% | $5,21,411.37M | 72.17 | |
| $147.18 | -0.59% | $3,62,834.91M | 117.74 | |
| $160.32 | -1.80% | $3,26,222.34M | 23.23 | |
| $185.48 | -0.69% | $2,87,691.54M | 24.32 | |
| $468.11 | +0.62% | $2,53,205.85M | 26.86 | |
| $169.73 | -0.67% | $2,10,522.74M | - | |
| $29.45 | +0.31% | $1,67,860.70M | 36.79 | |
| $41.09 | +0.96% | $1,39,300.36M | 11.15 | |
| $62.91 | +0.18% | $1,28,593.45M | 14.67 | |
| $48.43 | +0.41% | $1,16,984.89M | 23.63 |
An investment of $100 made 5 years ago in Emergent Biosolutions is now worth
$ 16.62
Resulting in a loss of
$ 83.38 (83.38%)
Note: Past profits do not guarantee future returns.
